


WHAT IS CLAIMED

1. A compound of Formula I



- 5 or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition which comprises a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10

3. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

15

4. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment pharmaceutical composition according to claim 2.

5. The method of claim 3, wherein the bacterial infection is due to *Mycobacterium tuberculosis*.

20

6. The method of claim 4, wherein the bacterial infection is due to *Mycobacterium tuberculosis*.

7. The method of claim 3, wherein the compound or the pharmaceutically acceptable salt thereof is administered orally, parenterally, or topically.

25

8. The method of claim 4, wherein the pharmaceutical composition is administered orally, parenterally, or topically.

9. The method of claim 5, wherein the *M. tuberculosis* is a drug resistant mycobacterial strain.


10. The method of claim 6, wherein the *M. tuberculosis* is a drug resistant mycobacterial strain.

11. The method of claim 3, further comprising the step of administering a second therapeutic agent for treating *M. tuberculosis*.

12. The method of claim 11, wherein the second therapeutic agent is selected from the group consisting of: ethambutol, pyrazinamide, isoniazid, levofloxacin, moxifloxacin, gatifloxacin, ofloxacin, kanamycin, amikacin, capreomycin, streptomycin, ethionamide, prothionamide, cycloserine, terididone, para-aminosalicylic acid, clofazimine, clarithromycin, amoxicillin-clavulanate, pretomanid, bedaquiline, GSK 3036656, gepotidacin, thiacetazone, meropenem-clavulanate, TBA-7371 a decaprenylphosphoryl- β -D-ribose 2'-oxidase (DprE1) Inhibitor, OPC-167832 from Otsuka Pharmaceutical, Telacebec (Q203) from Qurient Co., Ltd and thioridazine.

13. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection in a subject, or in the manufacture of a medicament for treating a bacterial infection in a subject.

14. A compound of Formula I



15. A pharmaceutical composition which comprises a therapeutically effective amount of the compound of claim 14 and a pharmaceutically acceptable carrier.

5

16. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment a therapeutically effective amount of the compound of claim 14.

17. A method for treating a bacterial infection which comprises administering to a subject in need of such treatment pharmaceutical composition according to claim 15.

10

18. The method of claim 16, wherein the bacterial infection is due to *Mycobacterium tuberculosis*.

19. The method of claim 17, wherein the bacterial infection is due to *Mycobacterium tuberculosis*.

15

20. The method of claim 16, wherein the compound or the pharmaceutically acceptable salt thereof is administered orally, parenterally, or topically.

20

21. The method of claim 17, wherein the compound or the pharmaceutically acceptable salt thereof is administered orally, parenterally, or topically.

22. The method of claim 18, wherein the *M. tuberculosis* is a drug resistant mycobacterial strain.

25

23. The method of claim 19, wherein the *M. tuberculosis* is a drug resistant

mycobacterial strain.

24. The method of claim 16, further comprising the step of administering a second therapeutic agent for treating *M. tuberculosis*.

5

25. The method of claim 24, wherein the second therapeutic agent is selected from the group consisting of: ethambutol, pyrazinamide, isoniazid, levofloxacin, moxifloxacin, gatifloxacin, ofloxacin, kanamycin, amikacin, capreomycin, streptomycin, ethionamide, prothionamide, cycloserine, terididone, para-aminosalicylic acid, clofazimine, clarithromycin, 10 amoxicillin-clavulanate, pretomanid, bedaquiline, GSK 3036656, gepotidacin, thiacetazone, meropenem-clavulanate, TBA-7371 a decaprenylphosphoryl- β -D-ribose 2'-oxidase (DprE1) Inhibitor, OPC-167832 from Otsuka Pharmaceutical, Telacebec (Q203) from Qurient Co., Ltd and thioridazine.

15

26. Use of the compound of claim 14, or a pharmaceutically acceptable salt thereof, for treating a bacterial infection in a subject, or in the manufacture of a medicament for treating a bacterial infection in a subject.